Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

Ascidian Therapeutics

HQ: Boston, MA source · ascidian-tx.com ↗

Clinical Phase 2

Location: Boston, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Stargardt Disease Stargardt Disease 1 Cone Rod Dystrophy Juvenile Macular Degeneration ACDN-01

2Trials (company is sponsor)

Timeline

Jun 20, 2024 Trial start —: Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH) source ↗
Jun 11, 2024 Trial start Phase 1/Phase 2: Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR) source ↗

Upcoming milestones

Aug 31, 2027 (ESTIMATED) · · Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH) · NCT06445322
Aug 1, 2030 (ESTIMATED) · Phase 1/Phase 2 · Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR) · NCT06467344

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT06445322	Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)	Not listed	Recruiting	Jun 20, 2024	Aug 31, 2027 (estimated)
NCT06467344	Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)	Phase 1/Phase 2	Recruiting	Jun 11, 2024	Aug 1, 2030 (estimated)